BioSpace News Archive

APEIRON Biologics AG, a biotechnology company with a broad preclinical and clinical pipeline and an approved product on the market, focusing on the discovery and development of novel cancer immunotherapies, announced today the appointment of Anderson Gaweco, M.D., Ph.D. as its Chief Medical and Scientific Officer (CMSO).

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company developing innovative therapeutics to treat life-threatening and devastating inflammatory diseases by targeting the complement system, a key component of the innate immune system, will host an R&D Day on Hidradenitis Suppurativa (HS) and its scientific and clinical experience with its breakthrough anti-C5a monoclonal antibody IFX-1, on Friday, September 7 in New York City.

BIOplus 2018 which takes place in Seoul next month (September 6th – 7th), will reveal the latest global intelligence in biotech and healthcare developments, focusing on game-changing insights to help bio companies grow their business.

Minomic has received a Notice of Allowance for the company’s patent covering its cell surface antigen for the diagnosis of prostate cancer

The a2 Milk Company™ today announced that it has secured exclusive distribution of a 3-pack a2 Milk® Whole Milk to Costco stores across the southeast.

Imagine this: your child is playing a game of soccer or basketball. As they go to kick the ball or defend a shot, they accidentally collide with another player and they both end up on the ground, dazed and a little stunned

Rockwell Medical, Inc. today announced that Jim McCarthy, has been appointed Senior Vice President, Corporate and Business Development, effective September 4, 2018.

Retains Board of Director and Scientific Advisory Board positions

Alimera Sciences, Inc. today announced that it has closed an agreement with Deerfield Management and certain of its affiliates (Deerfield) to exchange the Alimera Series B Convertible Preferred Stock previously held by Deerfield (the Series B) for newly issued Alimera Series C Convertible Preferred Stock (the Series C).

Medtronic plc (NYSE:MDT) today announced new findings from the CRYO4PERSISTENT AF clinical trial demonstrating improved quality of life, reduced symptoms from abnormal heart rhythms, and low incidence of reinterventions and repeat ablation procedures.